Combination treatment using thymosin α1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Cancer Immunology and Immunotherapy

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF01771450PMID 2126987PMCID PMC11038037
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide

  2004cited by this paper
• Thymosin α1 restores NK-cell activity and prevents tumor progression in mice immunosuppressed by cytostatics or X-rays

  2004cited by this paper
• Effect of low-dose cyclophosphamide therapy on specific and nonspecific T cell-dependent immune responses of spleen cells from mice bearing large MOPC-315 plasmacytomas

  2004cited by this paper
• Characterization of T-lymphocyte subpopulations infiltrating primary breast cancer

  2004cited by this paper
• Modulation of natural killer activity by thymosin alpha 1 and interferon

  2004cited by this paper
• Enhanced immune response and antitumor immunity with combinations of biological response modifiers.

  1989cited by this paper
• In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma.

  1989cited by this paper
• In vitro migration of rat large granular lymphocytes.

  1989cited by this paper
• Synergistic effect of thymosin α1 and αβ-interferon on NK activity in tumor-bearing mice

  1989cited by this paper
• Synergistic effect of thymosin alpha 1 and alpha beta-interferon on NK activity in tumor-bearing mice.

  1989cited by this paper
• Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors.

  1988cited by this paper
• Modulation of human natural killer cell cytotoxic activity, lymphokine production, and interleukin 2 receptor expression by thymic hormones.

  1987cited by this paper
• Modulation of immune response and tumor development in tumor-bearing mice treated by the thymic factor thymostimulin.

  1987cited by this paper
• The cytolytic and regulatory role of natural killer cells in human neoplasia.

  1986cited by this paper
• Reconstitution of T cell functions in aging mice by thymosin alpha 1.

  1986cited by this paper
• Modulation of interleukin 2 receptor expression on normal human lymphocytes by thymic hormones.

  1986cited by this paper
• Tumour inhibition by interleukin-2 at the tumour/host interface.

  1986cited by this paper
• Reconstitution of T cell functions in aging mice by thymosin α1

  1986cited by this paper
• ADOPTIVE CELLULAR IMMUNOTHERAPY1

  1985cited by this paper
• Changes in the host natural killer cell population in mice during tumor development. 1. Kinetics and in vivo significance.

  1985cited by this paper
• Biological Responses in Cancer

  1985cited by this paper
• THYMOSINS IN THE TREATMENT OF CANCER

  1985cited by this paper
• NATURAL KILLER (NK) CELLS: CHARACTERISTICS AND POSSIBLE ROLE IN RESISTANCE AGAINST TUMOR GROWTH

  1985cited by this paper
• Thymosin increases production of T-cell growth factor by normal human peripheral blood lymphocytes.

  1984cited by this paper
• Human natural killer cells: biologic and pathologic aspects.

  1984cited by this paper
• Phenotypic changes induced in the human thymic ALL cell line HPB-ALL by an ingenol ester, milliamin.

  1983cited by this paper
• Correlation between in vivo and in vitro studies of modulation of resistance to experimental Candida albicans infection by cyclophosphamide in mice

  1983cited by this paper
• Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells

  1982cited by this paper
• Thymosin fraction V and intensive combination chemotherapy. Prolonging the survival of patients with small-cell lung cancer.

  1979cited by this paper
• Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide.

  1977cited by this paper
• Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. I. Distribution of reactivity and specificity

  1975cited by this paper

• Aberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer

  2025cites this paper
• Acupoint Injection Combined with BCG-PSN and Thymosin Enteric-Coated Tablets Improve China Han Psoriasis Vulgaris by Regulating T Cell Subsets

  2025cites this paper
• Drug Repurposing in Oncology: A Strategic Pathway to Unlocking New Therapeutic Potential

  2025cites this paper
• Mechanism and clinical application of thymosin in the treatment of lung cancer

  2023cites this paper
• Impact of thymosin α1 as an immunomodulatory therapy on long-term survival of non-small cell lung cancer patients after R0 resection: a propensity score-matched analysis

  2021cites this paper
• Modified Thymosin Alpha 1 Distributes and Inhibits the Growth of Lung Cancer in Vivo

  2020cites this paper
• A Reappraisal of Thymosin Alpha1 in Cancer Therapy

  2019cites this paper
• Effect of a C-end rule modification on antitumor activity of thymosin α1.

  2018cites this paper
• Serum thymosin alpha 1 levels in normal and pathological conditions

  2018cites this paper
• Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy

  2018cites this paper
• Thymosin α1 Interacts with Hyaluronic Acid Electrostatically by Its Terminal Sequence LKEKK

  2017cites this paper
• Serum thymosin α 1 levels in patients with chronic inflammatory autoimmune diseases

  2016cites this paper
• Immune Modulation with Thymosin Alpha 1 Treatment.

  2016cites this paper
• Historical review on thymosin α1 in oncology: preclinical and clinical experiences

  2015influential citation
• Historical review of thymosin α 1 in infectious diseases

  2015influential citation
• Thymosin Apha 1–A Peptide Immune Modulator with a Broad Range of Clinical Applications

  2013cites this paper
• Thymosin α1 Activates Complement Receptor-Mediated Phagocytosis in Human Monocyte-Derived Macrophages

  2013cites this paper
• Inflammatory and immune reactions in response to chemotherapy-induced cell death

  2013cites this paper
• Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond

  2012cites this paper
• Thymosin α1 and cancer: action on immune effector and tumor target cells

  2012cites this paper
• Thymosin α1 as a stimulatory agent of innate cell‐mediated immune response

  2012cites this paper
• Prothymosin alpha: a ubiquitous polypeptide with potential use in cancer diagnosis and therapy

  2012cites this paper
• Immunomodulatory effects of cyclophosphamide and implementations for vaccine design

  2011cites this paper
• Combination strategies for enhancing the efficacy of immunotherapy in cancer patients

  2010cites this paper
• The anticancer immune response: indispensable for therapeutic success?

  2008cites this paper
• Thymosin α1 as a Chemopreventive Agent in Lung and Breast Cancer

  2007cites this paper
• Thymosin α1

  2007cites this paper
• Thymosin alpha1 as a chemopreventive agent in lung and breast cancer.

  2007cites this paper
• Thymosin alpha1: a historical overview.

  2007cites this paper
• IFN-alpha and novel strategies of combination therapy for cancer.

  2007cites this paper
• Thymosin Alpha 1

  2007cites this paper
• IFN‐α and Novel Strategies of Combination Therapy for Cancer

  2007cites this paper
• From Bench to Bedside

  2007cites this paper
• Thymosin al Down-regulates the Growth of Human Non-Small Cell Lung Cancer Cells in Vitro and in Vivo

  2006cites this paper
• Antitumour effect of OM-174 and cyclophosphamide on murine B16 melanoma in different experimental conditions.

  2005cites this paper
• Thymosin alpha(1) in combination with cytokines and chemotherapy for the treatment of cancer.

  2003cites this paper
• Thymosin α1 in combination with cytokines and chemotherapy for the treatment of cancer

  2003cites this paper
• Modulatory role of thymosin-alpha-1 in normal bone-marrow haematopoiesis and its effect on myelosuppression in T-cell lymphoma bearing mice.

  2002cites this paper
• Involvement of mitogen-activated protein kinases in the signal transduction pathway of bone marrow-derived macrophage activation in response to in vitro treatment with thymosin alpha 1.

  2002cites this paper
• RESTORATION OF IMMUNOCYTE FUNCTIONS BY THYMOSIN α1 IN CYCLOPHOSPHAMIDE-INDUCED IMMUNODEFICIENT MICE

  2001cites this paper
• Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer.

  2001cites this paper
• Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application.

  2000cites this paper
• Thymosinalpha1 is chemopreventive for lung adenoma formation in A/J mice.

  2000cites this paper
• High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma.

  1998cites this paper
• Evaluation of clinical efficacy and tolerability of intravenous high dose thymopentin in advanced melanoma patients

  1998cites this paper
• Combination therapy with BRMs in cancer and infectious diseases.

  1997cites this paper
• Peptides and growth factors in non-small cell lung cancer.

  1996cites this paper
• Biological activity and clinical efficacy of intravenous high-dose thymopentin in metastatic melanoma patients

  1996cites this paper
• Clinical and immunologic effects of T-activin therapy in early stage melanoma patients.

  1996cites this paper
• Efficacy of combination therapy with amantadine, thymosin alpha 1 and alpha/beta interferon in mice infected with influenza A virus.

  1996cites this paper
• Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a.

  1995cites this paper
• Recombinant interferon alpha 2a, thymopentin and low doses of cytosine arabinoside for the treatment of myelodysplastic syndromes: a pilot study.

  1995cites this paper
• Clinical applications of thymosin alpha-1.

  1994cites this paper
• Combination treatment with zidovudine, thymosin alpha 1 and interferon-alpha in human immunodeficiency virus infection.

  1994cites this paper
• Thymosin alpha 1 down-regulates the growth of human non-small cell lung cancer cells in vitro and in vivo.

  1993cites this paper
• Antitumor effect of thymosin alpha 1/interleukin-2 or thymosin alpha 1/interferon alpha,beta following cyclophosphamide in mice injected with highly metastatic Friend erythroleukemia cells.

  1993cites this paper
• Combination therapy with thymosin alpha 1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice.

  1992cites this paper
• Thymosin alpha one restores murine T-cell-mediated responses inhibited by in vivo cocaine administration.

  1992cites this paper